All you need is fungi: Exploring secondary metabolites as a source of novel amoebicidal agents
Authors:
- Maria Eduarda Deluca JoãoMJMaria Eduarda Deluca João
- Deisiane dos Santos MouraDMDeisiane dos Santos Moura
- Alexandra de Azevedo da RochaARAlexandra de Azevedo da Rocha
- Matheus Lopes BragaMBMatheus Lopes Braga
- Henrique R.M. AntoniolliHAHenrique R.M. Antoniolli
- Mauren Larangeira RamosMRMauren Larangeira Ramos
- Sofia Dietrich LochSLSofia Dietrich Loch
- Charley Christian StaatsCSCharley Christian Staats
Open Access
- 1 January 2026
- journal article
- Published by FapUNIFESP (SciELO) in Genetics and Molecular Biology
- Vol. 49 (suppl 1) , e20250199
Abstract
Free-living amoebae (FLAs) of the genus Acanthamoeba are opportunistic protozoa found in diverse environments. They can cause granulomatous amoebic encephalitis, especially in immunocompromised individuals, and Acanthamoeba keratitis, a painful corneal infection frequently associated with contact lens wearers. Effective treatments for Acanthamoeba infections are limited, with nitroimidazoles as the main pharmacological option, a class of drugs generally associated with side effects. Given the limited availability of vaccines and the low efficacy of existing drugs, the search for new therapeutic strategies is crucial. Interactions between fungi and predatory amoebae have driven the production of defensive fungal secondary metabolites (SMs) with potent amoebicidal properties. The evolutionary pressure from predatory amoebae has equipped fungi, particularly from the Aspergillus, Beauveria, and Fusarium genera, to produce a wide variety of defensive bioactive compounds, including non-ribosomal peptides, polyketides, and terpenes. Some examples of fungal-derived SMs include cephalosporins, mycophenolic acid, griseofulvin, pleuromutilins and lovastatin. Furthermore, gliotoxin and trypacidin from Aspergillus fumigatus exhibit amoebicidal activity by impairing key protozoan functions like phagocytosis. These findings highlight the potential of fungal SMs as novel amoebicidal agents. Exploring fungal biodiversity could lead to the discovery of innovative medicines, harnessing natural compounds to combat infections caused by Acanthamoeba species and other protozoan pathogens.Keywords
Funding Information
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (312994/2021-4)
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (405015/2023-2)
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (001)
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (312994/2021-4)
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (405015/2023-2)
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (001)
This publication has 98 references indexed in Scilit:
- PI3K signalling: the path to discovery and understandingNature Reviews Molecular Cell Biology, 2012
- Trypacidin, a Spore-Borne Toxin from Aspergillus fumigatus, Is Cytotoxic to Lung CellsPLOS ONE, 2012
- Are pleuromutilin antibiotics finally fit for human use?Annals of the New York Academy of Sciences, 2011
- IMP Dehydrogenase: Structure, Mechanism, and InhibitionChemical Reviews, 2009
- Therapeutic drug monitoring for mycophenolic acid in patients with autoimmune diseasesNephrology Dialysis Transplantation, 2008
- Acanthamoebicidal activity of Fusarium sp. Tlau3, an endophytic fungus from Thunbergia laurifolia Lindl.Parasitology Research, 2008
- Nonribosomal Peptide Synthetases Involved in the Production of Medically Relevant Natural ProductsMolecular Pharmaceutics, 2008
- Gliotoxin causes apoptosis and necrosis of rat Kupffer cells in vitro and in vivo in the absence of oxidative stress: Exacerbation by caspase and serine protease inhibitionJournal of Hepatology, 2007
- ANTIPROTOZOAL ANTIBIOTICS .2. ISOLATION AND CHARACTERIZATION OF TRYPACIDIN, A NEW ANTIBIOTIC, ACTIVE AGAINST TRYPANOSOMA CRUZI AND TOXOPLASMA GONDII1963
- The Treatment of Amebiasis with FumagillinScience, 1952